GlycoMimetics. has filed a patent for methods of treating cancer and related conditions by administering a compound of Formula (I) or its prodrug/salt. The patent includes treating AML, MDS, neutropenia, and mucositis. Claim 1-24 has been canceled. GlobalData’s report on GlycoMimetics gives a 360-degree view of the company including its patenting strategy. Buy the report here.
Smarter leaders trust GlobalData
According to GlobalData’s company profile on GlycoMimetics, Cancer treatment biomarkers was a key innovation area identified from patents. GlycoMimetics's grant share as of January 2024 was 32%. Grant share is based on the ratio of number of grants to total number of patents.
Treating cancer and related conditions with compound of formula (i)
See Also:
The patent application (Publication Number: US20230414641A1) describes a method for reducing or preventing side effects resulting from chemotherapy and radiotherapy in preparation for stem cell or bone marrow transplantation in a subject. The method involves administering a compound of Formula (I) to the subject, with the option of using the sodium salt of the compound. The compound is administered in specific amounts ranging from 200 mg to 4000 mg per day or 1 mg/kg to 100 mg/kg per day. The administration of the compound can be done before, during, or after the chemotherapy or radiotherapy treatment, with the subject subsequently undergoing bone marrow or stem cell transplantation.
The claims further specify that the chemotherapy or radiotherapy can include various agents such as melphalan, busulfan, fludarabine, carmustine, cyclophosphamide, etoposide, methotrexate, thiotepa, and topotecan. The method is particularly relevant for subjects diagnosed with acute myelogenous leukemia (AML) or myelodysplastic syndrome (MDS) and experiencing side effects like mucositis or neutropenia. The compound administration can help alleviate these side effects, with the potential for stem cell transplantation following the treatment. The patent application outlines a detailed approach to managing side effects associated with chemotherapy and radiotherapy in the context of preparing for transplantation, offering a potentially valuable solution for improving patient outcomes in these medical scenarios.
To know more about GlobalData’s detailed insights on GlycoMimetics, buy the report here.
Premium Insights
From
The gold standard of business intelligence.
Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.
GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.
GlobalData Patent Analytics tracks bibliographic data, legal events data, point in time patent ownerships, and backward and forward citations from global patenting offices. Textual analysis and official patent classifications are used to group patents into key thematic areas and link them to specific companies
